cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.14457/cu.the.2016.34
title: Effect of multidirectional reach training on dynamic balance in individuals with stroke

description: The aim of this study was to investigate the effect of multidirectional reach training on dynamic balance in individuals with stroke. Sixteen participants with stroke were recruited and randomly assigned into two groups, experimental and control. Participants in the experimental group were trained with the multidirectional reach training for 30 minutes and conventional physical therapy 30 minutes/day, 3 days/week for 4 weeks. Participants in the control group were received a conventional physical therapy for 30 minutes/day, 3 days /week for 4 weeks. The outcomes were limits of stability, weight bearing squat, multi-directional reach test, Fullerton advance balance scale, and Fugl Meyer Assessment. All of the outcome measures were measured at pre-training (Wk0), post-training (Wk4), and follow-up (Wk8). A two-way repeat measurement ANOVA was conducted to address the research questions. At post- training, and follow-up, the results showed that participants in the experimental group reported improvement of dynamic balance than the control group. Furthermore, Fullerton advance balance scale which refers to activity was more improve at follow-up in the experimental group than control group. The result of this study provides evidence that multidirectional reach training is effective for improve dynamic balance in individuals with stroke.
DOI: 10.14457/cu.the.2019.33
title: Effects and mechanisms of anacardium occidentale and glochidion zeylanicum leaf extracts on neuroprotective, neuritogenesis, oxidative stress resistance and anti-aging properties.

description: Aging is the primary risk factor for most neurodegenerative diseases and can negatively affect the quality of life. Neurodegenerative diseases are linked to neuronal cell death and neurite outgrowth impairment that are often caused by oxidative stress. As people want to live longer and healthier, healthy nutrition has been increasingly received much attention in recent years. Several studies reported a positive correlation between antioxidants in foods and longevity. Natural products from food supplements and medicinal plants with antioxidant properties could be promising candidates for fighting against various aging-related diseases and promoting longevity. Leaf extracts from A. occidentale (AO) and G. zeylanicum (GZ) have been of great interest due to their pronounced antioxidant effects. However, the anti-oxidant and anti-aging effects of AO and GZ leaf extracts still have not been reported. The current study aims to document beneficial effects of leaf extracts from AO and GZ extracts with neuroprotective, neuritogenesis, oxidative stress resistance properties and lifespan extension in the cultured neuronal (HT22 and Neuro-2a) cells and the C. elegans model. In cultured neuronal cell models, the AO and GZ extracts have a protective effect against glutamate/H2O2-mediated oxidative stress-induced cell death via inhibition of ROS accumulation, up-regulation of endogenous antioxidant enzymes, and the increase of the SIRT1-Nrf2 signaling pathway. The AO and GZ extracts increase neurite outgrowth mediated Ten-4 transmembrane protein. In C.elegans models, the AO and GZ extracts mediated the survival rate of nematodes under oxidative stress by stimulation stress-response genes (SOD-3 and GST-4), attenuating intracellular reactive oxygen species (ROS) accumulation via DAF-16/FoxO and SKN-1/Nrf-2 signaling pathway. The AO and GZ extracts exhibited anti-aging activities and enhanced longevity by improving pharyngeal pumping function, attenuation of pigment accumulation (lipofuscin) and a lifespan extension in wild-type worm. Collectively, this study is the first report about the phytochemical composition of A. occidentale and G. zeylanicum along with neuroprotective, neuritogenesis, antioxidant and anti-aging effects in cultured neuronal cells (In vitro) and C. elegans models (In vivo). Our novel findings could initiate further applications of AO and GZ leaf extracts as natural products beneficial to humans for developing new treatment and protection aging-related diseases in the future.
DOI: 10.21258/1632792
title: Inventario forestale nazionale svizzero - Tabella n. 897978
DOI: 10.21258/1629170
title: Inventario forestale nazionale svizzero - Tabella n. 892049
DOI: 10.6084/m9.figshare.13414664
title: Supplementary Material for: There is a Strong Association between Early Preeclampsia and Congenital Heart Defects: A Large Population-Based, Retrospective Study

description: <b><i>Objective:</i></b> The aim of this study was to determine the prevalence of congenital heart defects and examine their association with preeclampsia (PE). <b><i>Methods:</i></b> A clinical-based, retrospective study was conducted in Shenzhen between 2004 and 2017. Data were collected from Shenzhen Maternal and Child Health Hospital Medical Record Database. This study included all infants who were born at the hospital with or without heart defects and their mothers (<i>N</i> = 177,434 newborns). Data processing and analysis were performed by SPSS23.0 (Chicago, IL, USA). <b><i>Results:</i></b> 6,852 women (3.9%) were diagnosed as PE and 1,289 newborns (7.30 per 1,000) have congenital heart disease (CHD). Prevalence of CHD in newborns of women with PE is 15.8 per 1,000 significantly higher than the overall prevalence (7.30 per 1,000). CHD in newborns has strong association with PE, especially early-onset PE (adjusted OR 3.29 and 95% CI 2.15–5.03) and severe PE (adjusted OR 2.75 and 95% CI 2.13–3.56). Among those with CHD, infants of preeclamptic women had higher prevalence of tetralogy of Fallot (43.78 vs. 28.14 per 100,000), atrial septal defect (335.67 vs. 53.93 per 100,000), ventricular dysplasia (102.16 vs. 89.69 per 100,000), and ventricular septal defect (525.39 vs. 212.22 per 100,000) than pregnant women with non-PE. <b><i>Conclusion:</i></b> PE, especially early-onset PE and severe PE, is strongly associated with offspring CHD. Our results help advance the current understanding of the association between PE and offspring CHD. So preventing PE and reducing PE may have a beneficial effect on the offspring CHD.
DOI: 10.21258/1639182
title: Inventario forestale nazionale svizzero - Tabella n. 891882
DOI: 10.6084/m9.figshare.13414664.v1
title: Supplementary Material for: There is a Strong Association between Early Preeclampsia and Congenital Heart Defects: A Large Population-Based, Retrospective Study

description: <b><i>Objective:</i></b> The aim of this study was to determine the prevalence of congenital heart defects and examine their association with preeclampsia (PE). <b><i>Methods:</i></b> A clinical-based, retrospective study was conducted in Shenzhen between 2004 and 2017. Data were collected from Shenzhen Maternal and Child Health Hospital Medical Record Database. This study included all infants who were born at the hospital with or without heart defects and their mothers (<i>N</i> = 177,434 newborns). Data processing and analysis were performed by SPSS23.0 (Chicago, IL, USA). <b><i>Results:</i></b> 6,852 women (3.9%) were diagnosed as PE and 1,289 newborns (7.30 per 1,000) have congenital heart disease (CHD). Prevalence of CHD in newborns of women with PE is 15.8 per 1,000 significantly higher than the overall prevalence (7.30 per 1,000). CHD in newborns has strong association with PE, especially early-onset PE (adjusted OR 3.29 and 95% CI 2.15–5.03) and severe PE (adjusted OR 2.75 and 95% CI 2.13–3.56). Among those with CHD, infants of preeclamptic women had higher prevalence of tetralogy of Fallot (43.78 vs. 28.14 per 100,000), atrial septal defect (335.67 vs. 53.93 per 100,000), ventricular dysplasia (102.16 vs. 89.69 per 100,000), and ventricular septal defect (525.39 vs. 212.22 per 100,000) than pregnant women with non-PE. <b><i>Conclusion:</i></b> PE, especially early-onset PE and severe PE, is strongly associated with offspring CHD. Our results help advance the current understanding of the association between PE and offspring CHD. So preventing PE and reducing PE may have a beneficial effect on the offspring CHD.
DOI: 10.6084/m9.figshare.13065986
title: Gastric cancer lymph node data set

description: This is a dataset of pathological lymph nodes for gastric cancer. It can be used to test a gastric cancer lymph node metastasis detection model proposed in "Predicting gastric cancer outcome from resected lymph node histopathology images using deep learning".<br>
DOI: 10.6084/m9.figshare.13065986.v32
title: Gastric cancer lymph node data set

description: This is a dataset of pathological lymph nodes for gastric cancer. It can be used to test a gastric cancer lymph node metastasis detection model proposed in "Predicting gastric cancer outcome from resected lymph node histopathology images using deep learning".<br>
DOI: 10.21258/1638293
title: Inventario forestale nazionale svizzero - Tabella n. 896915
DOI: 10.21258/1667796
title: Inventario forestale nazionale svizzero - Tabella n. 897098
DOI: 10.4225/08/579965db0ffd9
title: SRAD sky view factor modelled using the 1" DEM-S

description: Mean monthly solar radiation was modelled across Australia using topography from the 1 arcsecond resolution SRTM-derived DEM-S and climatic and land surface data. The SRAD model (Wilson and Gallant, 2000) was used to derive: • Incoming short-wave radiation on a sloping surface • Short-wave radiation ratio (shortwave on sloping surface / shortwave on horizontal surface) • Incoming long-wave radiation • Outgoing long-wave radiation • Net long-wave radiation • Net radiation • Sky view factor All radiation values are in MJ/m2/day except for short-wave radiation ratio which has no units. The sky view factor is the fraction of the sky visible from a grid cell relative to a horizontal plane. The radiation values are determined for the middle day of each month (14th or 15th) using long-term average atmospheric conditions (such as cloudiness and atmospheric transmittance) and surface conditions (albedo and vegetation cover). They include the effect of terrain slope, aspect and shadowing (for sun positions at 5 minute intervals from sunrise to sunset), direct and diffuse radiation and sky view. The 3 arcsecond resolution versions of these radiation surfaces have been produced from the 1 arcsecond resolution surfaces, by aggregating the cells in a 3x3 window and taking the mean value. The data in this collection are available at 1 arcsecond resolution as 1x1 degree tiles (ESRI grid format) or as a single grid mosaic of Australia (TIFF format), and at 3 arcsecond resolution as a single grid of Australia (TIFF format).
DOI: 10.21258/1653166
title: Inventario forestale nazionale svizzero - Tabella n. 897055
DOI: 10.21258/1661817
title: Inventario forestale nazionale svizzero - Tabella n. 898225
DOI: 10.21258/1633136
title: Inventario forestale nazionale svizzero - Tabella n. 898818
DOI: 10.21258/1655250
title: Inventario forestale nazionale svizzero - Tabella n. 898998
DOI: 10.21258/1661956
title: Inventario forestale nazionale svizzero - Tabella n. 897481
DOI: 10.21258/1645998
title: Inventario forestale nazionale svizzero - Tabella n. 891839
DOI: 10.21258/1655478
title: Inventario forestale nazionale svizzero - Tabella n. 902055
DOI: 10.21258/1653286
title: Inventario forestale nazionale svizzero - Tabella n. 897969
DOI: 10.21258/1672224
title: Inventario forestale nazionale svizzero - Tabella n. 899061
DOI: 10.21258/1663926
title: Inventario forestale nazionale svizzero - Tabella n. 897058
DOI: 10.21258/1636374
title: Inventario forestale nazionale svizzero - Tabella n. 891922
DOI: 10.5519/qd.m4gxjoho
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.21258/1671046
title: Inventario forestale nazionale svizzero - Tabella n. 891697
DOI: 10.6084/m9.figshare.13147324.v1
title: QMOF Database

description: This repository hosts the Quantum MOF (QMOF) database – a dataset of quantum-chemical properties for over 14,000 metal–organic framework structures.<br>Please refer to the following GitHub repository for a description of the files hosted here, supplemental files/scripts, and other related information: https://github.com/arosen93/QMOF.<br>The pre-print corresponding to this work can be found at: https://doi.org/10.26434/chemrxiv.13147616.<br>
DOI: 10.21258/1652531
title: Inventario forestale nazionale svizzero - Tabella n. 898175
DOI: 10.21258/1669173
title: Inventario forestale nazionale svizzero - Tabella n. 899637
DOI: 10.21258/1646100
title: Inventario forestale nazionale svizzero - Tabella n. 897835
DOI: 10.21258/1649161
title: Inventario forestale nazionale svizzero - Tabella n. 892930
DOI: 10.21258/1668311
title: Inventario forestale nazionale svizzero - Tabella n. 897203
DOI: 10.21258/1639895
title: Inventario forestale nazionale svizzero - Tabella n. 897563
DOI: 10.21258/1649509
title: Inventario forestale nazionale svizzero - Tabella n. 899070
DOI: 10.21258/1664835
title: Inventario forestale nazionale svizzero - Tabella n. 897658
DOI: 10.21258/1658293
title: Inventario forestale nazionale svizzero - Tabella n. 899068
DOI: 10.5517/ccdc.csd.cc23hngr
title: CCDC 1951464: Experimental Crystal Structure Determination

description: Related Article: Zhi-Qiang Zhu, Dong Guo, Jiu-Jian Ji, Xiao Zhu, Juan Tang, Zong-Bo Xie, Zhang-Gao Le|2020|J.Org.Chem.|85|15062|doi:10.1021/acs.joc.0c01940
DOI: 10.5517/ccdc.csd.cc24wdwb
title: CCDC 1992552: Experimental Crystal Structure Determination

description: Related Article: Yi He, Liangliang Song, Chao Liu, Danjun Wu, Zhenghua Li, Luc Van Meervelt, Erik V. Van der Eycken|2020|J.Org.Chem.|85|15092|doi:10.1021/acs.joc.0c01972
DOI: 10.21258/1632980
title: Inventario forestale nazionale svizzero - Tabella n. 897036
DOI: 10.5517/ccdc.csd.cc25mnhz
title: CCDC 2014891: Experimental Crystal Structure Determination

description: Related Article: Dan Li, Minmin Zhang, Yuling Yang, Tianyu Peng, Dongxu Yang, Wei Gao, Rui Wang|2020|Org.Lett.|22|9229|doi:10.1021/acs.orglett.0c03417
DOI: 10.21258/1668955
title: Inventario forestale nazionale svizzero - Tabella n. 897410
DOI: 10.5517/ccdc.csd.cc267b2w
title: CCDC 2032827: Experimental Crystal Structure Determination

description: Related Article: Takashi Asako, Shin Suzuki, Shuhei Tanaka, Eisuke Ota, Junichiro Yamaguchi|2020|J.Org.Chem.|85|15437|doi:10.1021/acs.joc.0c02218
DOI: 10.5517/ccdc.csd.cc267b3x
title: CCDC 2032828: Experimental Crystal Structure Determination

description: Related Article: Takashi Asako, Shin Suzuki, Shuhei Tanaka, Eisuke Ota, Junichiro Yamaguchi|2020|J.Org.Chem.|85|15437|doi:10.1021/acs.joc.0c02218
DOI: 10.5517/ccdc.csd.cc267b4y
title: CCDC 2032829: Experimental Crystal Structure Determination

description: Related Article: Takashi Asako, Shin Suzuki, Shuhei Tanaka, Eisuke Ota, Junichiro Yamaguchi|2020|J.Org.Chem.|85|15437|doi:10.1021/acs.joc.0c02218
DOI: 10.5517/ccdc.csd.cc267b5z
title: CCDC 2032830: Experimental Crystal Structure Determination

description: Related Article: Takashi Asako, Shin Suzuki, Shuhei Tanaka, Eisuke Ota, Junichiro Yamaguchi|2020|J.Org.Chem.|85|15437|doi:10.1021/acs.joc.0c02218
DOI: 10.21258/1644950
title: Inventario forestale nazionale svizzero - Tabella n. 899521
DOI: 10.21258/1635630
title: Inventario forestale nazionale svizzero - Tabella n. 897921
DOI: 10.21258/1669127
title: Inventario forestale nazionale svizzero - Tabella n. 902268
DOI: 10.21258/1656011
title: Inventario forestale nazionale svizzero - Tabella n. 891934
DOI: 10.21258/1628043
title: Inventario forestale nazionale svizzero - Tabella n. 891821
DOI: 10.21258/1670323
title: Inventario forestale nazionale svizzero - Tabella n. 892835
DOI: 10.6084/m9.figshare.13414718
title: Supplementary Material for: Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany

description: <b><i>Introduction:</i></b> Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. <b><i>Methods:</i></b> We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. <b><i>Results:</i></b> Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period (<i>p</i> &lt; 0.0001). After 3 months of IFX therapy, work productivity and activity increased by an average of 12.6 and 17.1%, respectively. Patient’s clinical outcome was markedly improved as the total CD activity index (CDAI) sum score continuously decreased from baseline to month 24 and the mean score of the total inflammatory bowel disease questionnaire (IBDQ) changed substantially from 141 at baseline to 172 after 24 months of IFX treatment. Additionally, the number of work incapacity days declined. Recently, no new safety issues of IFX have been identified. <b><i>Conclusion:</i></b> In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.
DOI: 10.6084/m9.figshare.13414718.v1
title: Supplementary Material for: Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany

description: <b><i>Introduction:</i></b> Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. <b><i>Methods:</i></b> We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. <b><i>Results:</i></b> Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period (<i>p</i> &lt; 0.0001). After 3 months of IFX therapy, work productivity and activity increased by an average of 12.6 and 17.1%, respectively. Patient’s clinical outcome was markedly improved as the total CD activity index (CDAI) sum score continuously decreased from baseline to month 24 and the mean score of the total inflammatory bowel disease questionnaire (IBDQ) changed substantially from 141 at baseline to 172 after 24 months of IFX treatment. Additionally, the number of work incapacity days declined. Recently, no new safety issues of IFX have been identified. <b><i>Conclusion:</i></b> In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.
DOI: 10.6084/m9.figshare.13414754
title: Danshen (Salvia miltiorrhiza) genome (Chr6)

description: This is the assembled chr6 genome sequences of Salvia miltiorrhiza used in article Expansion within the CYP71D subfamily in Salvia miltiorrhiza drove the heterocyclization that characterizes tanshinone biosynthesis.<br><br>All scaffolds are uploaded to NCBI Genome Center under bioproject PRJNA682867. This chr6 is a pseudo-chromosome data assembled using Hi-C technology. <br>
DOI: 10.6084/m9.figshare.13414754.v1
title: Danshen (Salvia miltiorrhiza) genome (Chr6)

description: This is the assembled chr6 genome sequences of Salvia miltiorrhiza used in article Expansion within the CYP71D subfamily in Salvia miltiorrhiza drove the heterocyclization that characterizes tanshinone biosynthesis.<br><br>All scaffolds are uploaded to NCBI Genome Center under bioproject PRJNA682867. This chr6 is a pseudo-chromosome data assembled using Hi-C technology. <br>
DOI: 10.21258/1647604
title: Inventario forestale nazionale svizzero - Tabella n. 899307
DOI: 10.6084/m9.figshare.12029589.v1
title: Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study

description: <b>Background:</b> In precision cancer medicine, the challenge is to prioritize DNA driver events, account for resistance markers, and procure sufficient information for treatment that maintains patient safety. The MetAction project, exploring how tumor molecular vulnerabilities predict therapy response, first established the required workflow for DNA sequencing and data interpretation (2014–2015). Here, we employed it to identify molecularly matched therapy and recorded outcome in end-stage cancer (2016–2019). <b>Material and methods:</b> Metastatic tissue from 26 patients (16 colorectal cancer cases) was sequenced by the Oncomine assay. The study tumor boards interpreted called variants with respect to sensitivity or resistance to matched therapy and recommended single-agent or combination treatment if considered tolerable. The primary endpoint was the rate of progression-free survival 1.3-fold longer than for the most recent systemic therapy. The objective response rate and overall survival were secondary endpoints. <b>Results:</b> Both common and rare actionable alterations were identified. Thirteen patients were found eligible for therapy following review of tumor sensitivity and resistance variants and patient tolerability. The interventions were inhibitors of ALK/ROS1-, BRAF-, EGFR-, FGFR-, mTOR-, PARP-, or PD-1-mediated signaling for 2–3 cases each. Among 10 patients who received treatment until radiologic evaluation, 6 (46% of the eligible cases) met the primary endpoint. Four colorectal cancer patients (15% of the total study cohort) had objective response. The only serious adverse event was a transient colitis, which appeared in 1 of the 2 patients given PD-1 inhibitor with complete response. Apart from those two, overall survival was similar for patients who did and did not receive study treatment. <b>Conclusions:</b> The systematic MetAction approach may point forward to a refined framework for how to interpret the complexity of sensitivity <i>versus</i> resistance and patient safety that resides in tumor sequence data, for the possibly improved outcome of precision cancer medicine in future studies. <b>ClinicalTrials.gov, identifier:</b> NCT02142036